Responder patients had mutations around the rapidly accelerated fibrosarcoma (RAF)-rat sarcoma (RAS)-ERK pathway including KRAS/BRAF and MEK-related mutations that predicted the profiles to have stronger expression of PD-L1. The gene discussed is MAPK1; the disease is fibrosarcoma.